Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells
2001
Inhibiting Prostate Cancer Growth with RAR Antagonists
publication
Evidence: moderate
Author Information
Author(s): Hammond L A, Krinks C H Van, Durham J, Tomkins S E, Burnett R D, Jones E L, Chandraratna R A S, Brown G
Primary Institution: University of Birmingham Medical School
Hypothesis
RARĪ³-regulated gene transcription is necessary for the survival and maintenance of prostate epithelium.
Conclusion
Novel RAR antagonists are more potent than traditional treatments and may be useful in treating prostate carcinoma.
Supporting Evidence
- Novel synthetic antagonists of RARs were developed to avoid serum retinoid interference.
- AGN194310 inhibited colony formation by prostate carcinoma lines at low concentrations.
- AGN194310 is significantly more potent than all-trans retinoic acid against cell lines.
- PC3 and DU145 cells do not express RARĪ², affecting their response to certain antagonists.
Takeaway
Scientists found new drugs that can stop prostate cancer cells from growing and even make them die.
Methodology
Developed synthetic RAR antagonists and tested their effects on prostate carcinoma cell lines in serum-free conditions.
Limitations
The study does not specify the long-term effects of these antagonists in vivo.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website